The stock of OptimizeRx Corp (NASDAQ: OPRX) has increased by 40.22 when compared to last closing price of 4.14.Despite this, the company has seen a gain of 15.87% in its stock price over the last five trading days. seekingalpha.com reported 2025-03-12 that OptimizeRx Corporation (NASDAQ:OPRX ) Q4 2024 Results Conference Call March 12, 2025 8:30 AM ET Company Participants Steve Silvestro – President Edward Stelmakh – Chief Financial Officer and Chief Operational Officer Andrew D’Silva – Senior Vice President of Corporate Finance Conference Call Participants Jared Haase – William Blair Anderson Schock – B. Riley Constantine Davides – Citizens JMP Richard Baldry – ROTH Capital David Grossman – Stifel Financial Eric Martinuzzi – Lake Street Jeff Garro – Stephens, Inc Operator Good morning, everyone, and thank you for joining OptimizeRx’s Fourth Quarter and Full Year Fiscal 2024 Earnings Conference Call.
Is It Worth Investing in OptimizeRx Corp (NASDAQ: OPRX) Right Now?
The 36-month beta value for OPRX is at 1.62. Analysts have varying views on the stock, with 4 analysts rating it as a “buy,” 2 rating it as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for OPRX is 15.73M, and currently, shorts hold a 8.95% of that float. The average trading volume for OPRX on March 12, 2025 was 183.47K shares.
OPRX’s Market Performance
OPRX’s stock has seen a 15.87% increase for the week, with a 2.56% rise in the past month and a 8.30% gain in the past quarter. The volatility ratio for the week is 9.23%, and the volatility levels for the past 30 days are at 8.00% for OptimizeRx Corp The simple moving average for the past 20 days is 6.82% for OPRX’s stock, with a -20.65% simple moving average for the past 200 days.
Analysts’ Opinion of OPRX
Many brokerage firms have already submitted their reports for OPRX stocks, with RBC Capital Mkts repeating the rating for OPRX by listing it as a “Sector Perform.” The predicted price for OPRX in the upcoming period, according to RBC Capital Mkts is $6 based on the research report published on January 08, 2025 of the current year 2025.
Stephens, on the other hand, stated in their research note that they expect to see OPRX reach a price target of $5.50. The rating they have provided for OPRX stocks is “Equal-Weight” according to the report published on December 20th, 2024.
B. Riley Securities gave a rating of “Buy” to OPRX, setting the target price at $18.50 in the report published on July 25th of the previous year.
OPRX Trading at 7.50% from the 50-Day Moving Average
After a stumble in the market that brought OPRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -60.78% of loss for the given period.
Volatility was left at 8.00%, however, over the last 30 days, the volatility rate increased by 9.23%, as shares surge +8.58% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +17.61% upper at present.
During the last 5 trading sessions, OPRX rose by +21.36%, which changed the moving average for the period of 200-days by -51.63% in comparison to the 20-day moving average, which settled at $5.45. In addition, OptimizeRx Corp saw 19.44% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at OPRX starting from FEBBO WILLIAM J, who purchase 20,000 shares at the price of $5.01 back on Dec 12 ’24. After this action, FEBBO WILLIAM J now owns 601,253 shares of OptimizeRx Corp, valued at $100,220 using the latest closing price.
Stock Fundamentals for OPRX
Current profitability levels for the company are sitting at:
- -0.15 for the present operating margin
- 0.63 for the gross margin
The net margin for OptimizeRx Corp stands at -0.17. The total capital return value is set at -0.09. Equity return is now at value -20.97, with -16.72 for asset returns.
Based on OptimizeRx Corp (OPRX), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at 1.97. The debt to equity ratio resting at 0.02. The interest coverage ratio of the stock is -4.52.
Currently, EBITDA for the company is -22.67 million with net debt to EBITDA at 0.92. When we switch over and look at the enterprise to sales, we see a ratio of 1.03. The receivables turnover for the company is 2.41for trailing twelve months and the total asset turnover is 0.54. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.23.
Conclusion
In conclusion, OptimizeRx Corp (OPRX) has had a better performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
